Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCR001 in de novo living donor renal transplant
NCT03995901Phase 3Terminated
- Sponsor
- Talaris Therapeutics
- Start
- Oct 2019
- Primary completion
- Feb 2023
- Modality
- Bone Marrow HSCs, Peripheral Blood HSCs
- Countries
- 1
01
Overview
A Phase 3 trial of FCR001 in kidney transplant rejection, sponsored by Talaris Therapeutics. Started Oct 2019; status: terminated.
02
Drugs
FCR001
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT03995901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03995901.